Pay in 4 interest-free payments of $5.03 Learn more
Ships within 48 hours · Estimated delivery Sep 29 - Oct 4
National Institutes of Health
Knock-off versions of Eli Lilly's retatrutide, hailed as a potential 'new Ozempic', are being sold directly to US consumers Eli Lilly sparked enthusiasm about the future of retatrutide when it announced in June that Phase 2 trial results showed the drug led to an average weight loss of up to 24% over 48 weeks Eli Lilly sparked enthusiasm about the future of retatrutide when it announced in June that Phase 2 trial results showed the drug led to an average weight loss of up to 24% over 48 weeks
Check expiration dates, as potency diminishes over time
(2016) 5:e18640
US$ 26.56
US$ 22.76
US$ 25.62
US$ 29.38
US$ 27.22
US$ 28.90
US$ 23.33
